Trial · NCT03843853
Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer
NCT03843853, Phase 2, Withdrawn, The First Affiliated Hospital with Nanjing Medical University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer. Trials, record NCT03843853. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03843853
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer
- NCT number
- NCT03843853
- Status
- Withdrawn
- Phases
- Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Conditions
- Colorectal Neoplasms
- Interventions
- Pemetrexed, S-1, Bevacizumab
- First posted
- 2019-02-18
- Last updated
- 2022-07-25
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free Survival(PFS) | From assignment of the first subject to 3 months later after the last participant is recruited.The last participant will be recruited before November 1,2021 | PFS was defined as the time from assignment to disease progression radiological/clinical or death due to any cause, whichever occurs first. Subjects without progression or death at the time of analysis were censored at their last date of tumor evaluation. |
| Secondary | Overall Survival (OS) | From assignment of the first subject until 40 death events observed, up to 2 years. | OS is defined as the time from date of assignment to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact. |
| Secondary | Disease control rate (DCR) | From assignment of the first subject to 3 months later after the last participant is recruited.The last participant will be recruited before November 1,2021 | DCR is defined as the percentage of subjects whose best response was not Progressive Disease (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST) (= total number of Complete Response (CR) + total number of Partial Response (PR) + total number of Stable Disease (SD) |
| Secondary | Objective response rate(ORR) | From assignment of the first subject to 3 months later after the last participant is recruited.The last participant will be recruited before November 1,2021 | The percentage of subjects with total number of Complete Response (CR) + total number of Partial Response (PR) |
| Secondary | Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 | From assignment of the first subject to 3 months later after the last participant is recruited.The last participant will be recruited before November 1,2021 | adverse events will be assessed according to CTCAE v4.0, including hematological and non-hematological adverse events. Non-hematological adverse events will be collected by patients reported outcomes questionaire. The adverse events of interest include hypertension,hand-foot syndrome,proteinuria,hoarseness,rash,etc.The dose reduction and drug discontinuance due to adverse events will also be recorded. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03843853
GET https://conductscience.org/api/trials/v1/NCT03843853/registered